..Writing.
The combination of androgen deprivation therapy, an injection of commonly used hormones, plus radiation of the pelvic lymph nodes has controlled nearly 90% of the prostate cancer of clinical trial patients for five years, according to research. In addition, it has shown that prostate cancer patients who did not receive this combination therapy had a five-year survival in 70% of cases.
Prostate cancer patients who did not receive combination therapy had a five-year survival in 70% of cases
“We can now confirm that pelvic lymph node therapy in conjunction with androgen deprivation therapy, or even as a stand-alone treatment option, greatly improves outcomes in patients with postoperative prostate cancer.”has assured the president of the Department of Oncology at the Cedars Cancer Institute (United States).
The study has analyzed 1,716 patients between March 31, 2008 and March 30, 2015. The patients were separated into three groups. Group one received salvage prostate bed radiotherapy, standard radiation directed at the area where the prostate used to be before it was surgically removed. These patients had a mean 5-year survival of 71%.
The study has analyzed 1,716 patients between March 31, 2008 and March 30, 2015
The second group received standard radiation treatment, in combination with androgen deprivation therapy. They had a median five-year survival of 81%. The third group received salvage radiation therapy to the prostate bed, androgen deprivation therapy, and radiation to the pelvic lymph nodes. These patients had a five-year freedom from progression of more than 87%.
The researchers note that men with postoperative prostate cancer can have excellent outcomes. Especially if radiation is given early, when PSA levels are at their lowest, and in combination with proven therapies, as this new research suggests.
Complementary news
–
